logo_image
Headline: Poolbeg Pharma PLC Announces Notification of Major Holdings
Location: UK
Post Date: Jul 10, 2024 9:24 AM
TAG ID: awire165114
DocID: 887060
Word Count: approx. 600 words
 
 
Full story:


LONDON, UNITED KINGDOM / ACCESSWIRE / July 10, 2024 / TR-1: Standard form for notification of major holdings

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i

1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii : Poolbeg Pharma PLC

1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate)

Non-UK issuer

2. Reason for the notification (please mark the appropriate box or boxes with an "X")

An acquisition or disposal of voting rights X

An acquisition or disposal of financial instruments

An event changing the breakdown of voting rights

Other (please specify) iii :

3. Details of person subject to the notification obligation iv

Name

Michael Kelly

City and country of registered office (if applicable)

4. Full name of shareholder(s) (if different from 3.) v

Name

City and country of registered office (if applicable)

5. Date on which the threshold was crossed or reached vi :

4 July 2024

6. Date on which issuer notified (DD/MM/YYYY):

9 July 2024

7. Total positions of person(s) subject to the notification obligation

% of voting rights attached to shares (total of 8. A) % of voting rights through financial instruments (total of 8.B 1 + 8.B 2) Total of both in % (8.A + 8.B)

Total number of voting rights held in issuer vii

Resulting situation on the date on which threshold was crossed or reached 5.2%

5.2% 26,039,455

Position of previous notification (if

applicable) 4.8%





8. Notified details of the resulting situation on the date on which the threshold was crossed or reached viii

A: Voting rights attached to shares

Class/type of shares

ISIN code (if possible)

Number of voting rights ix

% of voting rights Direct (DTR5.1) Indirect (DTR5.2.1) Direct (DTR5.1) Indirect (DTR5.2.1)

GB00BKPG7Z60

26,039,455

5.2%



SUBTOTAL 8. A 26,039,455 5.2%

B 1: Financial Instruments according to DTR5.3.1R (1) (a)

Type of financial instrument

Expiration date x

Exercise/ Conversion Period xi

Number of voting rights that may be acquired if the instrument is

exercised/converted.

% of voting rights



SUBTOTAL 8. B 1

B 2: Financial Instruments with similar economic effect according to DTR5.3.1R (1) (b)

Type of financial instrument

Expiration date x

Exercise/ Conversion Period xi

Physical or cash

settlement xii

Number of voting rights

% of voting rights





SUBTOTAL 8.B.2

9. Information in relation to the person subject to the notification obligation (please mark the

applicable box with an "X")

Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer xiii

Full chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held starting with the ultimate controlling natural person or legal entity xiv (please add additional rows as necessary) X Name xv % of voting rights if it equals or is higher than the notifiable threshold % of voting rights through financial instruments if it equals or is higher than the notifiable threshold Total of both if it equals or is higher than the notifiable threshold

Michael Kelly



















10. In case of proxy voting, please identify:

Name of the proxy holder

The number and % of voting rights held

The date until which the voting rights will be held

11. Additional information xvi



Place of completion

Dublin, Ireland

Date of completion

9 July 2024

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com .

SOURCE: Poolbeg Pharma PLC View the original press release on accesswire.com

 
Please login to download this Story